Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1

Dig Dis Sci. 2006 Jun;51(6):1043-6. doi: 10.1007/s10620-006-8003-1.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain / etiology
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • DNA / analysis
  • Diagnosis, Differential
  • Female
  • Gastrointestinal Stromal Tumors / complications
  • Gastrointestinal Stromal Tumors / diagnosis*
  • Gastrointestinal Stromal Tumors / diagnostic imaging
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / surgery
  • Humans
  • Imatinib Mesylate
  • Jejunal Neoplasms / complications
  • Jejunal Neoplasms / diagnosis*
  • Jejunal Neoplasms / diagnostic imaging
  • Jejunal Neoplasms / drug therapy
  • Jejunal Neoplasms / pathology
  • Jejunal Neoplasms / surgery
  • Mutation
  • Neurofibromatosis 1 / complications
  • Neurofibromatosis 1 / diagnosis*
  • Neurofibromatosis 1 / pathology
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Proto-Oncogene Proteins c-kit / genetics
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • DNA
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • Receptor, Platelet-Derived Growth Factor alpha